These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35967377)

  • 1. Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension.
    Sanges S; Guerrier T; Duhamel A; Guilbert L; Hauspie C; Largy A; Balden M; Podevin C; Lefèvre G; Jendoubi M; Speca S; Hachulla É; Sobanski V; Dubucquoi S; Launay D
    Front Immunol; 2022; 13():954007. PubMed ID: 35967377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity.
    Lanteri A; Sobanski V; Langlois C; Lefèvre G; Hauspie C; Sanges S; Lambert M; Morell-Dubois S; Hatron PY; Hachulla E; Launay D; Dubucquoi S
    Autoimmun Rev; 2014 Sep; 13(9):974-80. PubMed ID: 25067821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
    Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
    Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension.
    Didriksen H; Molberg Ø; Mehta A; Jordan S; Palchevskiy V; Fretheim H; Gude E; Ueland T; Brunborg C; Garen T; Midtvedt Ø; Andreassen AK; Lund-Johansen F; Distler O; Belperio J; Hoffmann-Vold AM
    Front Immunol; 2022; 13():991743. PubMed ID: 36211384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.
    Guillén-Del-Castillo A; Meseguer ML; Fonollosa-Pla V; Giménez BS; Colunga-Argüelles D; Revilla-López E; Rubio-Rivas M; Ropero MJC; Argibay A; Barberá JA; Salas XP; Meñaca AM; Vuelta ABM; Padrón AL; Comet LS; Morera JAD; González-Echávarri C; Mombiela T; Ortego-Centeno N; González MM; Tolosa-Vilella C; Blanco I; Subías PE; Simeón-Aznar CP; ;
    Sci Rep; 2022 Mar; 12(1):5289. PubMed ID: 35347225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.
    Sanges S; Rice L; Tu L; Valenzi E; Cracowski JL; Montani D; Mantero JC; Ternynck C; Marot G; Bujor AM; Hachulla E; Launay D; Humbert M; Guignabert C; Lafyatis R
    Ann Rheum Dis; 2023 Mar; 82(3):365-373. PubMed ID: 36600187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
    Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
    J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis.
    Didriksen H; Molberg Ø; Fretheim H; Gude E; Jordan S; Brunborg C; Palchevskiy V; Garen T; Midtvedt Ø; Andreassen AK; Distler O; Belperio J; Hoffmann-Vold AM
    Arthritis Rheumatol; 2021 Jul; 73(7):1277-1287. PubMed ID: 33497027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
    Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: A systematic review and meta-analysis.
    Zhang Y; Qin D; Qin L; Yang X; Luo Q; Wang H
    Joint Bone Spine; 2022 Mar; 89(2):105287. PubMed ID: 34601113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension.
    Di Benedetto P; Guggino G; Manzi G; Ruscitti P; Berardicurti O; Panzera N; Grazia N; Badagliacca R; Riccieri V; Vizza CD; Radchenko G; Liakouli V; Ciccia F; Cipriani P; Giacomelli R
    Arthritis Res Ther; 2020 Jun; 22(1):127. PubMed ID: 32487240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
    Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
    Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension.
    Kolstad KD; Khatri A; Donato M; Chang SE; Li S; Steen VD; Utz PJ; Khatri P; Chung L
    Arthritis Res Ther; 2022 Feb; 24(1):39. PubMed ID: 35139913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
    Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
    BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
    Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
    Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.